Royalty Pharma plc Forms 3, 4 and 5: Other
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 7 rows in 2026. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2026-08-07: Reporting owner Legorreta Pablo G.; Form 4; Security LP interests in RPI US Partners 2019, LP; Transaction G Bona fide gift.
- 2026-08-07: Reporting owner Legorreta Pablo G.; Form 4; Security LP interests in RPI US Partners 2019, LP; Transaction Holding.
- 2026-08-07: Reporting owner Legorreta Pablo G.; Form 4; Security LP interests in RPI US Partners 2019, LP; Transaction Holding.
- 2026-08-07: Reporting owner Legorreta Pablo G.; Form 4; Security LP interests in RPI US Partners 2019, LP; Transaction Holding.
RPRX insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-08-07 | Legorreta Pablo G. Director, Officer (CEO, Chairman of the Board) | 4 | LP interests in RPI US Partners 2019, LP Derivative · Direct | G Bona fide gift | −30,000 662,701 owned after | $0.00 | $56.77 | 2026-08-07 |
| 2026-08-07 holding as of filing | Legorreta Pablo G. Director, Officer (CEO, Chairman of the Board) | 4 | LP interests in RPI US Partners 2019, LP Derivative · Indirect · By Legorreta Investments LLC | Holding | 3,707,488 owned after | no price filed | 2026-08-07 | |
| 2026-08-07 holding as of filing | Legorreta Pablo G. Director, Officer (CEO, Chairman of the Board) | 4 | LP interests in RPI US Partners 2019, LP Derivative · Indirect · By Legorreta Investments II LLC | Holding | 1,832,363 owned after | no price filed | 2026-08-07 | |
| 2026-08-07 holding as of filing | Legorreta Pablo G. Director, Officer (CEO, Chairman of the Board) | 4 | LP interests in RPI US Partners 2019, LP Derivative · Indirect · By Spouse | Holding | 147,014 owned after | no price filed | 2026-08-07 | |
| 2026-08-07 | Coyne Terrance P. Officer (EVP & CFO) | 4 | Class E Ordinary Shares Derivative · Indirect · See Footnote (2) | G Bona fide gift | −18,500 1,788,777 owned after | $0.00 | $56.77 | 2026-08-07 |
| 2026-08-07 | Urist Marshall Officer (EVP, Research & Investments) | 4 | LP interests in RPI US Partners 2019, LP Derivative · Indirect · By Sandy Lamm LLC | G Bona fide gift | −3,000 244,412 owned after | $0.00 | $56.77 | 2026-08-07 |
| 2026-01-06 holding as of filing | McGivern Arthur Richard Officer (EVP, Investments & GC) | 3 | Class E Ordinary Shares Derivative · Indirect · (m) | Holding | no price filed | 2026-01-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |